Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, th ...